In the race to develop a haemophilia B gene therapy Uniqure now has the upper hand.
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Digging into the sales forecasts for gene therapies shows just how low their penetration is expected to be. Could biopharma come to regret its high-price, low-volume…
The private UK group could steal the thunder of rivals like Spark, Uniqure and Biomarin.
Padua gambit seems to have worked as new gene therapy looks the equal of Pfizer/Spark Therapeutics.
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
Companies that want to play in rare diseases need to shop for gene therapies, but price tags are looking rich.